MMIT Reality Check on Glaucoma (Mar 2020)

According to our recent payer coverage analysis for glaucoma treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for glaucoma treatments shows that under the pharmacy benefit, about 60% of the lives under commercial formularies are covered without utilization management restrictions.

Trends: In March 2020, the FDA approved Allergan plc’s Durysta (bimatoprost implant) 10 mcg to treat open-angle glaucoma or ocular hypertension. This is the first intracameral biodegradable sustained-release implant for the indication.

0

0

0 Comments

0

0

• Reality Check